Comparative Pharmacology
Head-to-head clinical analysis: ELIDEL versus PROTOPIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELIDEL versus PROTOPIC.
ELIDEL vs PROTOPIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits T-cell activation by binding to macrophilin-12 (FKBP-12) and inhibiting calcineurin, thereby blocking cytokine transcription.
Tacrolimus, a calcineurin inhibitor, binds to FKBP-12 and inhibits calcineurin, thereby blocking dephosphorylation and nuclear translocation of NFAT, reducing transcription of pro-inflammatory cytokines (e.g., IL-2, IFN-γ) in T-cells.
Apply a thin layer of 1% cream to affected areas twice daily.
Apply a thin layer of 0.03% or 0.1% ointment to affected areas twice daily. Discontinue when lesions resolve. For adults, use 0.03% or 0.1%; 0.1% is not indicated for children.
None Documented
None Documented
Terminal elimination half-life: 30–45 hours (mean 35 hours) following topical application; clinically, twice-daily dosing ensures therapeutic concentrations.
Terminal half-life ranges from 6–20 hours in pediatric atopic dermatitis patients; prolonged in hepatic impairment (mean 8–35 hours).
Renal (negligible, <1% unchanged) and biliary/fecal (approximately 97% as metabolites); less than 1% of the dose is excreted renally as unchanged drug.
Primarily fecal (biliary) elimination of metabolites; <1% of parent drug excreted unchanged in urine.
Category C
Category C
Topical Calcineurin Inhibitor
Topical Calcineurin Inhibitor